QualityDipStocks / Health Care · Pharmaceuticals
Telix Pharmaceuticals TLX
Outside our quality screen, so we don’t track its dips. It’s 29% below its 52-week high.
Outside our quality screen. No fair value estimate for now: its free cash flow is negative.
Worth knowing
- Down 31% from its 52-week high while revenue grew 56%
From the data on this page, as of the last close. How we pick these
- Fair value est.
- n/a
- Market Value
- —
- Off 52-wk high
- −29%
- Risk vs market
- Market-likebeta 0.99
3 bullish · 5 bearish See why
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for TLX: negative free cash flow. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much TLX moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves about in line with the market, and its own price swings are 4.4× the S&P 500’s.
- Beta vs S&P 500
- 0.99
- Volatility
- 56% vs 13% SPY
- Correlation SPY
- 0.23
- Correlation QQQ
- 0.19
How it ranks
Where TLX stands vs every one of the 1,996 stocks we cover that has the number. Longer bar = better.
Top quarter on 1 of 4 measures
- Free cash flow yield−1.4% · free cash flow vs market capLowest 13%of 1,391
- Dividends + buybacks yield0% · cash paid out or used to retire shares, vs market capLowest 1%of 1,836
- Revenue growth, last 12 months+56% · vs the 12 months beforeTop 6%of 1,814
- Operating margin3.7% · of sales kept as operating profitLowest 22%of 1,288
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 3 of 5
GrowthSales grew 56% to $804M over the last 12 months vs the 12 months before (SEC filings).
GrowthSales compounded 55% a year from FY2023 to FY2025.
Balance sheetOperating income covers interest 165× over.
Top bearish points 5 of 5
ValuationFree cash flow is negative (−$43M over the last 12 months), so there’s no cash-flow value under the price.
ProfitabilityLost $7M over the last 12 months (net income, SEC filings).
ProfitabilityGross margin narrowed to 53.1% in FY2025 from 62.9% in FY2023 (SEC filings).
ProfitabilityReturn on equity fell 6 points in two fiscal years, to -2% in FY2025.
QualityDoesn’t pass our quality screen: no positive free cash flow; ROE under 12% and ROIC under 10%; net debt 4.7× EBITDA (limit 3×).
All fundamentals
FCF yield -1.4% · ROE -2% · Sales +56%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/anegative free cash flow
- FCF yield
- −1.4%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 3.86×
- Price / book
- 7.46×
- Market cap
- $3.1Blisted
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $804M
- Sales growth, 12 months
- +55.6%vs the 12 months before
- Sales growth, 3 yrs
- +55.4%/yrfrom FY2023
- Diluted EPS, 12 months
- −$0.02
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$7M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- 53.1%
- Operating margin
- 3.7%
- Net margin
- −0.9%
- FCF margin
- −5.3%
- Return on equity
- −2%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $142M
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- 164.5×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- −$43M
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- n/ano quarterly diluted share count
- Stock-based comp
- n/anot reported in its SEC filings
Trailing 12 months to Dec 31, 2025; balance sheet at Dec 31, 2025. From Telix Pharmaceuticals’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $-0.1B · Sales +22%
- Free cash flow, 12 months−$0.1B
- Free-cash-flow yield-1.4%
- Free-cash-flow margin−7%
- Gross margin48%
- Operating margin10%
- Return on invested capital8%
- Return on equity7%
- Sales growth (latest quarter vs year-ago quarter)+22%
- Net debt / EBITDA4.7×
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $9.05
- 52-wk lowlowest close, 1 year$6.41−29.2%
- PriceMon Nov 2 close$9.05you are here
- 52-wk highhighest close, 1 year$12.83+41.8%
Momentum & 52-week range
RSI 35 · 5 days +0.7%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
TLX is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Telix Pharmaceuticals in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 1:01 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.